These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 4643285)

  • 1. Accumulation in vitro of 35 S-chlorpromazine in the neuromelanin of human substantia nigra and locus coeruleus.
    Lindquist NG
    Arch Int Pharmacodyn Ther; 1972 Nov; 200(1):190-5. PubMed ID: 4643285
    [No Abstract]   [Full Text] [Related]  

  • 2. Accumulation of drugs on melanin.
    Lindquist NG
    Acta Radiol Diagn (Stockh); 1973; 325():1-92. PubMed ID: 4198914
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoradiography of 35S-chlorpromazine: accumulation and retention in melanin-bearing tissues.
    Lindquist NG; Ullberg S
    Adv Biochem Psychopharmacol; 1974; 9(0):413-23. PubMed ID: 4857754
    [No Abstract]   [Full Text] [Related]  

  • 5. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for specific phases in the development of human neuromelanin.
    Fedorow H; Halliday GM; Rickert CH; Gerlach M; Riederer P; Double KL
    Neurobiol Aging; 2006 Mar; 27(3):506-12. PubMed ID: 15916835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localization and characterization of angiotensin II receptor binding sites in the human basal ganglia, thalamus, midbrain pons, and cerebellum.
    Allen AM; Paxinos G; McKinley MJ; Chai SY; Mendelsohn FA
    J Comp Neurol; 1991 Oct; 312(2):291-8. PubMed ID: 1748734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical review of the function of neuromelanin and an attempt to provide a unified theory.
    Nicolaus BJ
    Med Hypotheses; 2005; 65(4):791-6. PubMed ID: 15949901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferritin and neuromelanin "quantum dot" array structures in dopamine neurons of the substantia nigra pars compacta and norepinephrine neurons of the locus coeruleus.
    Rourk CJ
    Biosystems; 2018 Sep; 171():48-58. PubMed ID: 30048795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits.
    Beach TG; Sue LI; Walker DG; Lue LF; Connor DJ; Caviness JN; Sabbagh MN; Adler CH
    Acta Neuropathol; 2007 Oct; 114(4):419-24. PubMed ID: 17639428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depigmentation in the nerve cells of the substantia nigra and locus ceruleus in Parkinsonism.
    Forno LS; Alvord EC
    Adv Neurol; 1974; 5():195-202. PubMed ID: 4374062
    [No Abstract]   [Full Text] [Related]  

  • 12. Tissue binding of tritiated norepinephrine in pigmented nuclei of human brain.
    Ishii T; Friede RL
    Am J Anat; 1968 Jan; 122(1):139-44. PubMed ID: 5654500
    [No Abstract]   [Full Text] [Related]  

  • 13. A quantitative investigation of the substantia nigra in Huntington's disease.
    Oyanagi K; Takeda S; Takahashi H; Ohama E; Ikuta F
    Ann Neurol; 1989 Jul; 26(1):13-9. PubMed ID: 2528318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromelanin and Parkinson's disease.
    Marsden CD
    J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromelanin, neuroleptics and schizophrenia: hypothesis of an interaction between noradrenergic and dopaminergic system.
    Kaiya H
    Neuropsychobiology; 1980; 6(5):241-8. PubMed ID: 6106167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.
    Allen AM; MacGregor DP; Chai SY; Donnan GA; Kaczmarczyk S; Richardson K; Kalnins R; Ireton J; Mendelsohn FA
    Ann Neurol; 1992 Sep; 32(3):339-44. PubMed ID: 1416803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of catecholamine uptake sites in human brain as determined by quantitative [3H] mazindol autoradiography.
    Donnan GA; Kaczmarczyk SJ; Paxinos G; Chilco PJ; Kalnins RM; Woodhouse DG; Mendelsohn FA
    J Comp Neurol; 1991 Feb; 304(3):419-34. PubMed ID: 2022757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations in melanin content with age in the human substantia nigra.
    Mann DM; Yates PO; Barton CM
    Biochem Exp Biol; 1977; 13(2):137-9. PubMed ID: 616297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromelanin in the human brain: a review and atlas of pigmented cells in the substantia nigra.
    Usunoff KG; Itzev DE; Ovtscharoff WA; Marani E
    Arch Physiol Biochem; 2002 Oct; 110(4):257-369. PubMed ID: 12516659
    [No Abstract]   [Full Text] [Related]  

  • 20. Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules.
    Salazar M; Sokoloski TD; Patil PN
    Fed Proc; 1978 Aug; 37(10):2403-7. PubMed ID: 354974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.